Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Indian (NIFTY) Healthcare Sector Analysis

UpdatedFeb 26, 2026
DataAggregated Company Financials
Companies321
  • 7D1.3%
  • 3M-2.0%
  • 1Y9.5%
  • YTD0.3%

In the last week, the Healthcare industry is up 1.3%, with Sun Pharmaceutical Industries up 2.3%. Meanwhile, Inventurus Knowledge Solutions actually underperformed within the industry, shrinking 13% in the last week. This means that the industry has gained 9.5% over the past year. Looking forward, earnings are forecast to grow by 21% annually.

Sector Valuation and Performance

Has the Indian Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Thu, 26 Feb 2026₹30.5t₹5.9t₹780.2b28.4x39.1x5.1x
Sat, 24 Jan 2026₹28.8t₹5.7t₹768.8b29.8x37.4x5x
Mon, 22 Dec 2025₹30.4t₹5.7t₹772.5b33.3x39.3x5.3x
Wed, 19 Nov 2025₹30.5t₹5.7t₹765.9b32.5x39.9x5.4x
Fri, 17 Oct 2025₹30.7t₹5.5t₹732.5b34.8x41.9x5.6x
Sun, 14 Sep 2025₹30.8t₹5.5t₹730.1b36.1x42.1x5.6x
Tue, 12 Aug 2025₹29.9t₹5.4t₹729.9b35.7x41x5.5x
Thu, 10 Jul 2025₹30.2t₹5.3t₹727.2b35.9x41.5x5.7x
Sat, 07 Jun 2025₹29.3t₹5.3t₹728.5b36.9x40.2x5.5x
Mon, 05 May 2025₹28.3t₹5.2t₹684.9b32.7x41.3x5.4x
Wed, 02 Apr 2025₹27.6t₹5.2t₹680.3b33.4x40.6x5.3x
Fri, 28 Feb 2025₹26.4t₹5.2t₹682.3b31x38.7x5.1x
Sun, 26 Jan 2025₹28.4t₹5.1t₹650.5b35.1x43.7x5.6x
Tue, 24 Dec 2024₹29.4t₹5.0t₹648.1b37.4x45.3x5.8x
Thu, 21 Nov 2024₹27.9t₹5.0t₹642.9b36.7x43.5x5.6x
Sat, 19 Oct 2024₹29.3t₹4.9t₹605.3b43x48.5x6x
Mon, 16 Sep 2024₹29.5t₹4.9t₹605.3b43x48.7x6x
Wed, 14 Aug 2024₹27.1t₹4.8t₹598.7b36.5x45.3x5.6x
Fri, 12 Jul 2024₹25.3t₹4.7t₹550.5b38.8x46x5.4x
Sun, 09 Jun 2024₹23.7t₹4.6t₹546.0b33.8x43.5x5.1x
Tue, 07 May 2024₹23.2t₹4.6t₹512.8b35.5x45.3x5.1x
Thu, 04 Apr 2024₹23.1t₹4.6t₹512.7b34.8x45.1x5x
Sat, 02 Mar 2024₹22.7t₹4.6t₹512.5b35.1x44.4x5x
Mon, 29 Jan 2024₹21.4t₹4.4t₹478.6b37.7x44.7x4.8x
Wed, 27 Dec 2023₹20.1t₹4.4t₹476.2b35.1x42.3x4.6x
Fri, 24 Nov 2023₹19.2t₹4.4t₹476.1b33.4x40.3x4.4x
Sun, 22 Oct 2023₹18.0t₹4.3t₹450.6b31.7x39.9x4.2x
Tue, 19 Sep 2023₹18.2t₹4.3t₹451.5b32.4x40.2x4.3x
Thu, 17 Aug 2023₹17.8t₹4.2t₹448.2b30x39.8x4.2x
Sat, 15 Jul 2023₹16.7t₹4.1t₹425.6b28.2x39.3x4.1x
Mon, 12 Jun 2023₹15.4t₹4.1t₹425.6b27.8x36.1x3.8x
Wed, 10 May 2023₹14.7t₹4.0t₹388.3b28.5x37.8x3.7x
Fri, 07 Apr 2023₹13.5t₹3.9t₹372.9b26.4x36.2x3.5x
Sun, 05 Mar 2023₹13.1t₹3.9t₹373.6b26.4x35.2x3.4x
Price to Earnings Ratio

35.2x


Total Market Cap: ₹13.1tTotal Earnings: ₹373.6bTotal Revenue: ₹3.9tTotal Market Cap vs Earnings and Revenue0%0%0%
Indian Healthcare Sector Price to Earnings3Y Average 41.7x202420252026
Current Industry PE
  • Investors are relatively neutral on the Indian Healthcare industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PE ratio of 41.7x.
  • The industry is trading close to its 3-year average PS ratio of 5.0x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have grown 28% per year over the last three years.
  • Revenues for these companies have grown 15% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Indian Healthcare sector?

IN Market-0.97%
Healthcare1.31%
Biotech3.98%
Pharma1.78%
Life Sciences0.67%
Healthcare Services0.50%
Medical Equipment-1.72%
Healthtech-12.40%
Industry PE
  • Investors are most optimistic about the Biotech industry which is trading above its 3-year average PE ratio of 57.7x.
    • Analysts are expecting annual earnings growth of 57.3%, which is higher than its past year's earnings growth of 31.5% per year.
  • Investors are most pessimistic about the Pharma industry, which is trading close to its 3-year average of 36.6x.
Forecasted Growth
  • Analysts are most optimistic on the Biotech industry, expecting annual earnings growth of 57% over the next 5 years.
  • This is better than its past earnings growth rate of 31% per year.
  • In contrast, the Pharma industry is expected to see its earnings grow by 16% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
SUNPHARMA Sun Pharmaceutical Industries₹1.79k4.2%
+₹173.5b		8.4%PE39.3x
MANKIND Mankind Pharma₹2.28k11.8%
+₹99.2b		-0.6%PE52.8x
500420 Torrent Pharmaceuticals₹4.40k4.2%
+₹60.2b		47.3%PE65.5x
DIVISLAB Divi's Laboratories₹6.47k2.8%
+₹46.9b		15.3%PE69.3x
ALKEM Alkem Laboratories₹5.75k7.0%
+₹44.8b		24.7%PE29x

Latest News

500257
₹2,323.20
Lupin
7D
4.3%
1Y
22.8%
SYNGENE
₹425.90
Syngene International
7D
-2.8%
1Y
-37.1%

SYNGENE: Long Bristol Myers Partnership And VivaMed Collaboration Will Support Future Earnings Visibility

Analysts have trimmed their price target on Syngene International from ₹652.50 to ₹626.25, reflecting updated assumptions around the discount rate, profit margin and future P/E expectations. What's in the News VivaMed BioPharma announced a partnership with Syngene International that links VivaMed's AI driven discovery platform with Syngene's preclinical development capabilities, covering in vitro and in vivo pharmacology, biomarker work, assay development, translational study design and preclinical support (Key Developments).
FORTIS
₹963.65
Fortis Healthcare
7D
6.3%
1Y
56.5%

FORTIS: Governance Calendar And Margin Outlook Will Support Future Upside

Analysts have slightly increased their price target for Fortis Healthcare to ₹1,072.71 from ₹1,070.88, citing updated assumptions that incorporate modestly higher revenue growth, improved profit margins, and a lower future P/E multiple in their models. What's in the News A board meeting is scheduled for Feb 13, 2026 to consider and approve the unaudited standalone and consolidated financial results for the quarter and period ended Dec 31, 2025 (company filing).
APLLTD
₹729.60
Alembic Pharmaceuticals
7D
-4.9%
1Y
-6.0%

APLLTD: US Approvals And Margin Profile Will Guide A Steady Outlook

Analysts have maintained their fair value estimate for Alembic Pharmaceuticals at ₹845. They have made modest adjustments to assumptions around revenue growth, profit margin, and future P/E to reflect updated views on the company’s earnings profile, without changing the overall price target.
MANKIND
₹2,279.70
Mankind Pharma
7D
11.8%
1Y
-0.6%

MANKIND: Upcoming Results Will Support Further Upside Despite Modest Assumption Cuts

Analysts have trimmed their price target for Mankind Pharma from about ₹2,631 to about ₹2,537. This reflects slightly lower assumptions for revenue growth, profit margins and future P/E multiples, alongside a modestly reduced discount rate.
DIVISLAB
₹6,474.00
Divi's Laboratories
7D
2.8%
1Y
15.3%

DIVISLAB: Upcoming Results Review Will Shape Balanced Long Term Outlook

Narrative Update on Divi's Laboratories The analyst price target for Divi's Laboratories has been adjusted slightly higher from about ₹6,823 to roughly ₹6,870, with analysts pointing to small refinements in assumptions around discount rate, revenue growth, profit margin and future P/E as the drivers of this change. What's in the News A board meeting is scheduled for February 11, 2026, to review and approve unaudited standalone financial results for the quarter and nine months ended December 31, 2025 (company filing).
ALKEM
₹5,752.00
Alkem Laboratories
7D
7.0%
1Y
24.7%

ALKEM: Long Dated US Settlements And Dermatology Launch Will Support ReRating

Analysts have trimmed their price target for Alkem Laboratories from ₹7,056 to ₹6,913, reflecting updated views on revenue growth, profit margin assumptions and a slightly lower future P/E multiple. What's in the News Alkem and Axsome Therapeutics reached a settlement on patent litigation over SUNOSI, with Alkem receiving a license to sell a generic version in the US starting on or after March 1, 2040 (or September 1, 2040 if pediatric exclusivity is granted), subject to regulatory approvals and customary conditions (Axsome settlement announcement).
500420
₹4,400.20
Torrent Pharmaceuticals
7D
4.2%
1Y
47.3%

500420: Board Actions And Interim Dividend Will Shape Future Risk Balance

Analysts have revised their price target on Torrent Pharmaceuticals from ₹4,080 to ₹4,418, citing updated assumptions around revenue growth, profit margins and forward P/E as key drivers of this change. What's in the News Torrent Pharmaceuticals declared an interim dividend of ₹29 per equity share of ₹5, described as 580% of the face value, with payment or dispatch expected on or around 6 March 2026 (company announcement).
JSLL
₹636.20
Jeena Sikho Lifecare
7D
-9.1%
1Y
84.8%

JSLL: Higher Margin Outlook Will Support Future Upside Potential

Analysts have lifted their price target for Jeena Sikho Lifecare from ₹950 to ₹1,200, citing updated assumptions for revenue growth, higher profit margins, and a lower future P/E multiple in their refreshed valuation model. What's in the News A board meeting is scheduled on Feb 7, 2026 to review unaudited standalone and consolidated financial results for the quarter and nine months ended Dec 31, 2025, along with the limited review report, and to consider other items with the chairperson's approval (company filing).
COHANCE
₹308.35
Cohance Lifesciences
7D
-2.1%
1Y
-73.4%

COHANCE: FDA Compliance Remediation Will Support Confidence In Long Term Growth

Analysts have revised their fair value estimate for Cohance Lifesciences from about ₹733 to roughly ₹513, reflecting updated assumptions around slightly higher revenue growth, a lower projected profit margin, and a reduced future P/E multiple. What's in the News The U.S. FDA issued Warning Letter No. 718812 to Cohance Lifesciences regarding CGMP violations at its drug manufacturing facility in Medchal Malkajgiri, citing concerns around investigations of quality issues, cleaning validation, and cross contamination risks (Regulatory Authority – Enforcement Actions).
LAURUSLABS
₹1,092.75
Laurus Labs
7D
7.0%
1Y
101.2%

LAURUSLABS: Future Returns Will Rely On Confidence In Elevated P E Assumptions

Narrative Update: Laurus Labs Analyst Price Target Analysts have maintained their Laurus Labs price target at ₹913.47, citing largely unchanged assumptions around revenue, profit margins, discount rate, and forward P/E as the basis for keeping fair value steady. Analyst Commentary Analysts covering Laurus Labs are using a similar playbook to recent work on other education and healthcare names, where price targets are adjusted mainly on valuation inputs rather than big changes in growth assumptions.
HCG
₹574.60
HealthCare Global Enterprises
7D
-3.4%
1Y
14.1%

HCG: Rights Issue Plan And Margin Outlook Will Support Future Upside

Analysts have lifted their price target on HealthCare Global Enterprises from ₹857.76 to ₹900.00. They cite updated assumptions that reflect a slightly different revenue growth outlook, higher profit margin expectations, a revised discount rate, and a lower future P/E multiple.
SUNPHARMA
₹1,785.70
Sun Pharmaceutical Industries
7D
4.2%
1Y
8.4%

SUNPHARMA: Obesity And Diabetes Pipeline Will Drive Long Term Upside

Analysts have trimmed their price target on Sun Pharmaceutical Industries by around ₹2. This reflects updated assumptions on fair value, discount rate, revenue growth, profit margin, and future P/E that remain broadly consistent with their earlier view.
ZOTA
₹1,242.70
Zota Health Care
7D
-6.4%
1Y
50.5%

Why We're Not Concerned About Zota Health Care Limited's (NSE:ZOTA) Share Price

Feb 10
Why We're Not Concerned About Zota Health Care Limited's (NSE:ZOTA) Share Price
IKS
₹1,417.60
Inventurus Knowledge Solutions
7D
-14.5%
1Y
-22.8%

Inventurus Knowledge Solutions Limited (NSE:IKS) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year

Feb 07
Inventurus Knowledge Solutions Limited (NSE:IKS) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year
WOCKPHARMA
₹1,363.60
Wockhardt
7D
-2.1%
1Y
16.7%